Research Analysts Offer Predictions for Indivior PLC’s FY2025 Earnings (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) – Stock analysts at Northland Capmk dropped their FY2025 earnings estimates for Indivior in a research note issued on Tuesday, July 9th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $1.75 for the year, down from their prior forecast of $2.25. The consensus estimate for Indivior’s current full-year earnings is $1.80 per share.

Separately, Craig Hallum cut their price target on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday.

Indivior Trading Down 4.3 %

NASDAQ:INDV opened at $10.84 on Friday. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.92 and a quick ratio of 0.74. The business’s 50-day simple moving average is $16.41 and its 200-day simple moving average is $17.93. Indivior has a fifty-two week low of $9.14 and a fifty-two week high of $24.90. The stock has a market capitalization of $1.49 billion, a PE ratio of 1,084.00 and a beta of 0.69.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, April 25th. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.01). Indivior had a return on equity of 842.72% and a net margin of 0.44%. The business had revenue of $284.00 million for the quarter, compared to the consensus estimate of $300.00 million.

Institutional Investors Weigh In On Indivior

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Indivior by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,846,354 shares of the company’s stock worth $134,875,000 after buying an additional 90,673 shares during the last quarter. Norges Bank bought a new position in Indivior in the fourth quarter valued at approximately $36,011,000. UBS Group AG grew its stake in Indivior by 71.9% in the fourth quarter. UBS Group AG now owns 826,130 shares of the company’s stock valued at $12,615,000 after purchasing an additional 345,556 shares in the last quarter. Renaissance Group LLC increased its position in shares of Indivior by 6.1% during the 4th quarter. Renaissance Group LLC now owns 103,023 shares of the company’s stock worth $1,573,000 after purchasing an additional 5,896 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of Indivior during the 4th quarter worth approximately $649,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.